Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + fotemustine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ipilimumab + fotemustine is a combination therapy used primarily in the treatment of advanced or metastatic melanoma, including patients with brain metastases. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), thereby enhancing antitumor immune responses by blocking an inhibitory signal to T cells and promoting their activation and proliferation. Fotemustine is an alkylating agent of the nitrosourea class that can cross the blood-brain barrier and exerts its effect by causing DNA damage in tumor cells. The combination has demonstrated clinical activity in phase 2 trials for metastatic melanoma, including those with brain metastases[1][3][5][6]. Ipilimumab was developed by Bristol Myers Squibb.
- Brand names
- Yervoy
- Other names
- Ipilimumab and FotemustineNIBIT-M1 regimenNIBIT-M-1 regimenNIBIT-M 1 regimen
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on ipilimumab + fotemustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + fotemustine.